合成および生物学的抗リウマチ薬によるRAマネジメントに関する 2022 EULAR リコメンデーション
Smolen JS,
Landewé RBM,
Bergstra SA,
Kerschbaumer A,
Sepriano A,
Aletaha D,
Caporali R,
Edwards CJ,
Hyrich KL,
Pope JE,
de Souza S,
Stamm TA,
Takeuchi T,
Verschueren P,
Winthrop KL,
Balsa A,
Bathon JM,
Buch MH,
Burmester GR,
Buttgereit F,
Cardiel MH,
Chatzidionysiou K,
Codreanu C,
Cutolo M,
den Broeder AA,
El Aoufy K,
Finckh A,
Fonseca JE,
Gottenberg JE,
Haavardsholm EA,
Iagnocco A,
Lauper K,
Li Z,
McInnes IB,
Mysler EF,
Nash P,
Poor G,
Ristic GG,
Rivellese F,
Rubbert-Roth A,
Schulze-Koops H,
Stoilov N,
Strangfeld A,
van der Helm-van Mil A,
van Duuren E,
Vliet Vlieland TPM,
Westhovens R,
van der Heijde D
Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356
Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.
Since their initial development in 2010, updates to the EULAR recommendations have been produced every 3 years as insights have evolved, and new classification criteria, definitions of remission, treatment strategies, and drugs have emerged.
The task force agreed on 5 overarching principles and 11 recommendations concerning use of csDMARDs, GCs, bDMARDs and tsDMARDs.
